Peer-influenced content. Sources you trust. No registration required. This is HCN.

MashupMDPembrolizumab vs. Chemotherapy for Microsatellite Instability-High or Mismatch Repair-Deficient Metastatic CRC

In this updated analysis of the KEYNOTE-177 study, although pembrolizumab continued to show durable antitumor activity and fewer treatment-related adverse events compared with chemotherapy, there was no significant difference in overall survival between the two treatment groups.